0001558370-24-008704.txt : 20240529 0001558370-24-008704.hdr.sgml : 20240529 20240529071437 ACCESSION NUMBER: 0001558370-24-008704 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scorpius Holdings, Inc. CENTRAL INDEX KEY: 0001476963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262844103 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35994 FILM NUMBER: 24994002 BUSINESS ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-240-7133 MAIL ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: NightHawk Biosciences, Inc. DATE OF NAME CHANGE: 20220502 FORMER COMPANY: FORMER CONFORMED NAME: HEAT BIOLOGICS, INC. DATE OF NAME CHANGE: 20091117 8-K 1 scpx-20240529x8k.htm 8-K
0001476963falseNone0001476963us-gaap:CommonStockMember2024-05-292024-05-290001476963scpx:CommonstockpurchaserightsMember2024-05-292024-05-2900014769632024-05-292024-05-29

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 29, 2024

Scorpius Holdings, Inc.

(Exact name of registrant as specified in charter)

​

​

​

Delaware

001-35994

26-2844103

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

627 Davis Drive, Suite 300

Morrisville, North Carolina 27560

(Address of principal executive offices and zip code)

(919) 240-7133

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0002 par value per share

SCPX

NYSE American LLC

Common Stock Purchase Rights

   

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

​

Item 2.02 Results of Operations and Financial Condition.

On May 29, 2024, Scorpius Holdings, Inc., a Delaware corporation (the “Company”), issued the attached press release that included financial information for its quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 5.08. Shareholder Director Nominations.

 

To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

​

Item 8.01. Other Events.

 

The Company currently plans to hold its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on August 2, 2024. The Company record date for determining the stockholders of record who will be entitled to vote at the 2024 Annual Meeting will be close of business on June 13, 2024. The time and location of the 2024 Annual Meeting will be as set forth in the Company’s definitive proxy statement for the 2024 Annual Meeting to be filed with the Securities and Exchange Commission.

 

Because the scheduled date of the 2024 Annual Meeting is more than 30 days prior to the anniversary of the Company’s 2023 Annual Meeting of Stockholders, prior disclosed deadlines regarding the submission of stockholder proposals pursuant to Rule 14a-8 (“Rule 14a-8”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the 2024 Annual Meeting are no longer applicable. The Company is hereby providing notice of certain revised deadlines for the submission of stockholder proposals in connection with the 2024 Annual Meeting. In order for a stockholder proposal, submitted pursuant to Rule 14a-8, to be considered timely for inclusion in the Company’s proxy statement and form of proxy for the 2024 Annual Meeting, such proposal must be received by the Company by June 8, 2024. The Company has determined that June 8, 2024 is a reasonable time before the Company plans to begin printing and mailing its proxy materials. Therefore, in order for a stockholder to submit a proposal for inclusion in the Company’s proxy materials for the 2024 Annual Meeting, the stockholder must comply with the requirements set forth in Rule 14a-8, including with respect to the subject matter of the proposal, and must deliver the proposal and all required documentation to the Company no later than June 8, 2024. The public announcement of an adjournment or postponement of the date of the 2024 Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8.

 

Generally, timely notice of any director nomination or other proposal that any stockholder intends to present at the 2024 Annual Meeting, but does not seek to have included in the proxy materials pursuant to Rule 14a-8, must be delivered no later than June 8, 2024, which is the tenth day following the date of this Current Report on Form 8-K announcing the date of the 2024 Annual Meeting. Therefore, in order for a stockholder to timely submit a director nomination or other proposal that the stockholder intends to present at the 2024 Annual Meeting, the stockholder must deliver the director nomination or proposal to the Company no later than June 8, 2024.

 

In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by June 8, 2024, which is the tenth calendar day following the date of this Current Report on Form 8-K announcing the date of the 2024 Annual Meeting.

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

​

​

​

Exhibit
Number

    

Description

​

​

​

99.1

​

Press Release issued by Scorpius Holdings, Inc. May 29, 2024

104

​

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

Dated: May 29, 2024

SCORPIUS HOLDINGS, INC.

​

​

​

By:

/s/ Jeffrey Wolf

​

Name: 

Jeffrey Wolf

​

Title:

Chairman, President and
Chief Executive Officer

​

​

​

 EX-99.1 2 scpx-20240529xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

Scorpius Holdings Achieves 359% Year-Over-Year Increase
in Revenue for the First Quarter of 2024

Reduces operating expenses by 34% and net loss by 64%

Durham, NC – May 28, 2024 –Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the first quarter ended March 31, 2024.

Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are successfully executing our strategy to enhance revenue and reduce costs as we seek to become cash flow positive in the near future. This quarter is indicative of this goal as we achieved a 359% increase in revenue while reducing operating expenses by 34% over the same period last year. We believe this performance reinforces the growing demand for our services and our prudent financial management.  Moreover, we have built a highly scalable business model poised to generate meaningful cash flow as we continue to grow our sales and increase utilization of our state-of-the-art San Antonio campus, which we anticipate will allow us to achieve meaningful operating leverage. We are very confident that the future for Scorpius is brighter than ever, with significant industry-wide capacity shortages, and our growing revenue backlog, which stood at $10.8 million as of March 31, 2024.”

2023 Financial Results

For the three months ended March 31, 2024, the Company recognized $3.5 million of revenue from process development. For the three months ended March 31, 2023, the Company recognized $0.7 million of process development revenue and $0.1 million of license revenue. The increase in process development revenue was attributable to the expanded biomanufacturing operations and service offerings of the CDMO.

Cost of revenues were $0.9 million and $0.6 million for the three months ended March 31, 2024, and 2023, respectively, and primarily consisted of the direct cost of labor, overhead and material costs at Scorpius. The increase in cost of revenues was due to the expanded service offerings and completed milestone work on multiple CDMO contracts.

Research and development expenses were $3.9 million for the three months ended March 31, 2024, compared to $6.3 million for the three months ended March 31, 2023.

Selling, general and administrative expenses were $5.0 million and $6.5 million for the three months ended March 31, 2024, and 2023, respectively. The decrease of $1.5 million was primarily due to decreases in marketing expense of $0.5 million, consultant labor of $0.5 million, and stock-based compensation of $0.5 million.

For the three months ended March 31, 2024, the change in fair value of contingent earn-out receivable, related party, was $1.0 million. This change was primarily due to an increase in expected value of the earn-out due to a new contract received by Elusys Therapeutics.

Total non-operating income was $0.7 million for the three months ended March 31, 2024, which primarily consisted of $1.0  million from the sale of an intellectual property license, partially offset by $0.2 million of interest expense on finance leases, and $0.1 million change in fair value of convertible promissory note, related party. Total non-operating income was $0.1 million for the three months ended March 31, 2023, which primarily consisted of $0.2 million of interest income, $0.1 million of unrealized gain on short-term investment balances, partially offset by $0.2 million of interest expense on finance leases and other expense.

Net loss attributable to Scorpius was approximately $4.4 million, or ($0.16) per basic and diluted share, for the three months ended March 31, 2024, compared to approximately $12.8 million, or ($0.49) per basic and diluted share, for the three months ended March 31, 2023.

As of March 31, 2024, the Company had approximately $1.7 million in cash, cash equivalents, and short-term investments. On May 16, 2024, the Company consummated a public offering  resulting in aggregate gross proceeds of approximately $6.0 million, before deducting underwriting discounts and other offering expenses.

Scorpius Holdings, Inc.

Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as becoming cash flow positive in the near future, enhanced revenue and decreased operating expenses reinforcing the growing demand for the Company’s  services and its prudent financial management; the business model being poised to generate meaningful cash flow;  continuing to grow sales and increase utilization of the state-of-the-art San Antonio campus which will allow the Company to achieve meaningful operating leverage,  the future for Scorpius being brighter than ever. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its bookings  and continue

to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive;  the Company’s financing needs, its cash balance  being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as  a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman

+1 919 289 4017

ir@scorpiusbiologics.com

 GRAPHIC 3 scpx-20240529xex99d1001.jpg GRAPHIC begin 644 scpx-20240529xex99d1001.jpg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end EX-101.SCH 4 scpx-20240529.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 scpx-20240529_def.xml EX-101.DEF EX-101.LAB 6 scpx-20240529_lab.xml EX-101.LAB EX-101.PRE 7 scpx-20240529_pre.xml EX-101.PRE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 29, 2024
Document Type 8-K
Document Period End Date May 29, 2024
Entity File Number 001-35994
Entity Registrant Name Scorpius Holdings, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-2844103
Entity Address, Address Line One 627 Davis Drive
Entity Address, Adress Line Two Suite 300
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 240-7133
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001476963
Amendment Flag false
Common Stock  
Title of 12(b) Security Common Stock, $0.0002 par value per share
Trading Symbol SCPX
Security Exchange Name NYSEAMER
Common Stock Purchase Rights  
Title of 12(b) Security Common Stock Purchase Rights
Trading Symbol None
Security Exchange Name NYSEAMER
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document Information
May 29, 2024
Document Information:  
Document Type 8-K
Amendment false
CIK 0001476963
Registrant Name Scorpius Holdings, Inc.
Period End Date May 29, 2024
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200 - Document - Document Information Sheet http://xbrl.sec.gov/dei/role/document/DocumentInformation Document Information Cover 2 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:TradingSymbol - scpx-20240529x8k.htm 9 scpx-20240529.xsd scpx-20240529_def.xml scpx-20240529_lab.xml scpx-20240529_pre.xml scpx-20240529x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "scpx-20240529x8k.htm": { "nsprefix": "scpx", "nsuri": "http://scorpiusbiologics.com/20240529", "dts": { "schema": { "local": [ "scpx-20240529.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2014/extensible-enumerations.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023_def.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/rxp/2023/rxp-2023.xsd", "https://xbrl.sec.gov/snj/2023/snj-2023.xsd", "https://xbrl.sec.gov/snj/2023/snj-2023_def.xsd" ] }, "definitionLink": { "local": [ "scpx-20240529_def.xml" ] }, "labelLink": { "local": [ "scpx-20240529_lab.xml" ] }, "presentationLink": { "local": [ "scpx-20240529_pre.xml" ] }, "inline": { "local": [ "scpx-20240529x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 69, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_5_29_2024_To_5_29_2024_fCPsJx_HV0aTBX0BADjGXg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "scpx-20240529x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_29_2024_To_5_29_2024_fCPsJx_HV0aTBX0BADjGXg", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "scpx-20240529x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/DocumentInformation", "longName": "995200 - Document - Document Information", "shortName": "Document Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "Duration_5_29_2024_To_5_29_2024_fCPsJx_HV0aTBX0BADjGXg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "scpx-20240529x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "rxp_A": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "A", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Amount", "terseLabel": "Amount" } } }, "auth_ref": [] }, "country_AllCountriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "AllCountriesDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Countries [Domain]", "terseLabel": "All Countries" } } }, "auth_ref": [] }, "rxp_AllGovernmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "AllGovernmentsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Governments [Member]", "terseLabel": "All Governments" } } }, "auth_ref": [] }, "rxp_AllProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "AllProjectsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "All Projects [Member]", "terseLabel": "All Projects" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "terseLabel": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "rxp_Bonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Bonuses", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Bonuses", "terseLabel": "Bonuses" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "rxp_Cm": { "xbrltype": "conversionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Cm", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Currency Conversion Method", "terseLabel": "Curr. Conv. Method" } } }, "auth_ref": [] }, "rxp_Co": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Co", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Country", "terseLabel": "Country" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "auth_ref": [] }, "scpx_CommonstockpurchaserightsMember": { "xbrltype": "domainItemType", "nsuri": "http://scorpiusbiologics.com/20240529", "localname": "CommonstockpurchaserightsMember", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Common Stock Purchase Rights" } } }, "auth_ref": [] }, "rxp_CommunityAndSocial": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "CommunityAndSocial", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Community and Social Responsibility", "terseLabel": "Comm. Social Resp." } } }, "auth_ref": [] }, "rxp_CountryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "CountryAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Country [Axis]", "terseLabel": "Country:" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "rxp_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Dividends", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Dividends", "terseLabel": "Dividends" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "terseLabel": "Document Information", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "terseLabel": "All Entities", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "terseLabel": "Reporting Currency", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "rxp_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Fees", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Fees", "terseLabel": "Fees" } } }, "auth_ref": [] }, "rxp_GovernmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "GovernmentAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Government [Axis]", "terseLabel": "Government:" } } }, "auth_ref": [] }, "rxp_Gv": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Gv", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Government", "terseLabel": "Govt." } } }, "auth_ref": [] }, "rxp_InfrastructureImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "InfrastructureImprovements", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Infrastructure Improvements", "terseLabel": "Infrastructure" } } }, "auth_ref": [] }, "rxp_K": { "xbrltype": "yesItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "K", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind", "terseLabel": "In-kind" } } }, "auth_ref": [] }, "rxp_Km": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Km", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind Value Calculation", "terseLabel": "In-kind Calc." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity:", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "rxp_M": { "xbrltype": "extractionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "M", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Extraction Method", "terseLabel": "Ext. Method" } } }, "auth_ref": [] }, "rxp_P": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "P", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payment Type", "terseLabel": "Type" } } }, "auth_ref": [] }, "rxp_PaymentsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByCategoryTable", "lang": { "en-us": { "role": { "label": "Payments by Category [Table]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PaymentsByGovernmentTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByGovernmentTable", "lang": { "en-us": { "role": { "label": "Payments by Government [Table]", "terseLabel": "Payments, by Government:" } } }, "auth_ref": [] }, "rxp_PaymentsByProjectTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByProjectTable", "lang": { "en-us": { "role": { "label": "Payments by Project [Table]", "terseLabel": "Payments, by Project:" } } }, "auth_ref": [] }, "rxp_PaymentsDetailTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsDetailTable", "lang": { "en-us": { "role": { "label": "Payments Detail [Table]", "terseLabel": "Payments Detail:" } } }, "auth_ref": [] }, "rxp_PaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsLineItems", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payments [Line Items]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PmtAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PmtAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Pmt [Axis]", "terseLabel": "#" } } }, "auth_ref": [] }, "rxp_Pr": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Pr", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Project", "terseLabel": "Project" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "rxp_ProductionEntitlements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "ProductionEntitlements", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Production Entitlements", "terseLabel": "Prod. Entitlements" } } }, "auth_ref": [] }, "rxp_ProjectAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "ProjectAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Project [Axis]", "terseLabel": "Project:" } } }, "auth_ref": [] }, "rxp_R": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "R", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Resource", "terseLabel": "Resource" } } }, "auth_ref": [] }, "rxp_Royalties": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Royalties", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Royalties", "terseLabel": "Royalties" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "rxp_Sg": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Sg", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Segment", "terseLabel": "Segment" } } }, "auth_ref": [] }, "rxp_Sn": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Sn", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Subnational Jurisdiction", "terseLabel": "Subnat. Juris." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "rxp_Taxes": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Taxes", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Taxes", "terseLabel": "Taxes" } } }, "auth_ref": [] }, "rxp_TotalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "TotalPayments", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Total Payments", "terseLabel": "Total Payments" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://scorpiusbiologics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 19 0001558370-24-008704-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-008704-xbrl.zip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end XML 21 scpx-20240529x8k_htm.xml IDEA: XBRL DOCUMENT 0001476963 us-gaap:CommonStockMember 2024-05-29 2024-05-29 0001476963 scpx:CommonstockpurchaserightsMember 2024-05-29 2024-05-29 0001476963 2024-05-29 2024-05-29 0001476963 false None 8-K 2024-05-29 Scorpius Holdings, Inc. DE 001-35994 26-2844103 627 Davis Drive Suite 300 Morrisville NC 27560 919 240-7133 false false false false Common Stock, $0.0002 par value per share SCPX NYSEAMER Common Stock Purchase Rights NYSEAMER false